respiratori
viral
infect
frequent
respons
acut
deterior
clinic
condit
patient
underli
pulmonari
diseas
eg
chronic
obstruct
pulmonari
diseas
asthma
may
also
predispos
bacteri
infect
haemophilu
injuenza
streptococcu
pneumonia
staphylococcu
awe
viral
infect
upper
airway
frequent
patient
cystic
fibrosi
healthi
control
consequ
tend
major
caus
acut
deterior
lung
function
patient
cystic
fibrosi
consid
f
correspond
address
bacteri
especi
p
aeruginosu
onethird
preced
viral
previou
studi
compar
quantit
bacteriolog
analys
sputum
patient
cystic
fibrosi
studi
immun
respons
differ
viral
agent
patient
therefor
decid
determin
extent
respiratori
tract
infect
differ
virus
mycoplasma
pneumonia
coxiella
hurnetii
contribut
develop
acut
bronchopulmonari
exacerb
cystic
fibrosi
seventyf
patient
laboratori
clinic
sign
cystic
fibrosi
femal
male
mean
age
f
rang
year
includ
studi
shwachman
score
patient
lay
studi
period
novemb
april
sera
collectedbetween
one
serum
sampl
patient
median
valu
fiftytwo
per
cent
serum
sampl
taken
outpati
dr
von
haunersch
kinderspit
miinchen
admiss
hospit
hospit
stay
major
cfpatient
chronic
infect
month
pseudomona
aeruginosu
begin
studi
five
patient
harbour
p
aeruginosa
intermitt
airway
whilst
six
patient
free
pathogen
throughout
studi
two
patient
cystic
fibrosi
develop
infect
due
p
aeruginosu
start
studi
antibodi
influenza
influenza
b
influenza
c
virus
parainfluenza
virus
type
respiratori
syncyti
viru
rsv
adenoviru
pneumoniu
c
burnetii
determin
complement
fixat
accord
titer
adenoviru
mycoplasma
rsv
influenza
b
virus
c
burnetii
influenza
c
parainfluenza
virus
least
fourfold
rise
pair
serum
sampl
consid
indic
recent
infect
microbiolog
analys
sputum
perform
time
serolog
sputum
sigaantibodi
differ
lipopolysaccharid
antigen
p
aeruginosa
evalu
describ
elsewher
statist
calcul
wilcoxonmannwhit
test
test
fisher
exact
test
use
criteria
ender
previous
describ
found
viral
respiratori
infecti
episod
patient
cystic
fibrosi
taken
studi
infect
two
differ
viral
agent
time
occur
twice
influenza
adenoviru
influenza
b
adenoviru
multipl
respiratori
tract
viral
infect
found
seven
patient
least
month
two
episod
tabl
least
fourfold
titer
rise
complementfix
test
seen
viral
infect
four
case
first
serum
sampl
show
significantli
elev
antibodi
titer
tabl
influenza
viru
frequent
serolog
proven
viral
pathogen
x
follow
adenoviru
x
influenza
b
viru
x
parainfluenza
viru
serotyp
x
parainfluenza
viru
serotyp
rsv
x
found
serolog
evid
infect
influenza
c
viru
parainfluenza
viru
serotyp
pneumonia
c
burnetii
signific
differ
age
distribut
cystic
fibrosi
group
without
viral
infect
upper
airway
mean
age
compar
f
infect
parainfluenza
virus
seem
appear
frequent
younger
children
wherea
preval
viral
agent
differ
age
group
similar
age
distribut
cystic
fibrosi
patient
tabl
correl
carriag
p
aeruginosa
viral
infect
viral
infect
cystic
fibrosi
occur
entir
year
tabl
infect
influenza
b
virus
frequent
winter
spring
contrast
parainfluenza
virus
adenoviru
peak
summer
period
patient
cystic
fibrosi
viral
infect
upper
airway
requir
frequent
hospit
admiss
p
oool
stay
longer
p
ool
cystic
fibrosi
patient
without
proven
serolog
convers
tabl
greatest
part
serolog
proven
viral
infect
occur
home
tabl
accompani
acut
exacerb
respiratori
symptom
take
account
incub
period
day
differ
viral
agent
period
l
day
serolog
convers
viral
respiratori
diseas
may
hospitalacquir
infect
parainfluenza
virus
rsv
seen
outsid
hospit
infect
influenza
b
viru
adenovirus
tend
occur
hospit
three
four
adenoviru
infect
probabl
nosocomi
two
three
infect
influenza
b
viru
hospit
seen
time
winter
influenza
b
epidem
munich
analys
bacteri
flora
sputum
patient
cystic
fibrosi
found
pneumoniu
common
cfpatient
respiratori
viral
infect
without
evid
infect
contrast
pneumonia
h
enza
frequent
detect
sputum
cfpatient
viral
infect
upper
airway
versu
p
deterior
clinic
condit
pronounc
cough
increas
expector
loss
weight
reduct
lung
function
observ
cystic
fibrosi
patient
viral
infect
tabl
microbi
flora
sputum
cystic
fibrosi
patient
unchang
ratio
number
coloni
form
unit
cfu
per
millilitr
differ
bacteri
fungal
speci
sputum
viral
infect
number
cfusper
millilitr
prior
onset
smaller
greater
least
three
fold
increas
cfu
per
millilitr
ofsputum
found
viral
infect
mainli
p
aeruginosa
even
case
without
clinic
deterior
tabl
two
case
well
increas
number
cfu
per
millilitr
p
aeruginosa
aureu
h
influenza
appear
sputum
wherea
two
patient
signific
chang
detect
h
influenza
aureu
anoth
case
colonis
penicillin
resist
strain
aureu
either
aureu
h
infiuenzu
isol
sputum
viral
infect
like
prior
acut
exacerb
isol
rate
fungi
sputum
sampl
acut
exacerb
parallel
viral
infect
acut
exacerb
serolog
evid
viral
diseas
enough
sputum
determin
antip
aeruginosa
lipopolysaccharid
antibodi
pair
sputum
sampl
ospecif
sigaantibodi
show
increas
viral
respiratori
tract
infect
increas
sigaantibodi
sputum
seen
doubl
infect
infect
due
parainfluenza
viru
serotyp
infect
adenoviru
infect
influenza
b
viru
influenza
viru
evalu
serum
antibodi
titer
differ
viral
bacteri
respiratori
tract
pathogen
reveal
viral
infect
patient
cystic
fibrosi
frequenc
complet
reflect
real
incid
respiratori
tract
infect
patient
requir
sera
avail
assay
perform
antibodi
rhinovirus
coronaviru
echoviru
chfamydia
trachomati
legionellapneumophila
purpos
studi
show
whether
microbi
synerg
virus
caus
respiratori
tract
infect
bacteri
microflora
sputa
found
strong
evid
microbi
synerg
signific
chang
least
threefold
increas
cfu
per
millilitr
sputum
bacteri
sputum
flora
occur
clinic
deterior
patient
viral
ill
infect
may
decreas
mucociliari
clearanc
damag
respiratori
epithelium
suppress
host
defenc
mechan
facilit
bacteri
adher
multipl
pseudomona
aeruginosa
known
abil
adher
damag
epitheli
account
greatest
part
acut
bronchopulmonari
exacerb
reflect
increas
sputum
sigaantibodi
direct
oantigen
p
aeruginosa
time
even
case
without
appar
deterior
clinic
condit
number
cfu
p
aeruginosa
per
millilitr
sputum
increas
significantli
also
case
aureu
andor
h
infuenza
addit
pathogen
sputum
without
chang
number
cfu
p
aeruginosa
increas
colonis
aureu
h
influenza
secondari
viral
infect
agre
work
eichenwald
et
al
author
found
correl
adenovir
infect
upper
airway
newborn
infant
bacteri
colonis
nasopharynx
aureu
h
influenza
pneumonia
bhemolyt
streptococci
treatment
acut
respiratori
infect
cystic
fibrosi
antibiot
effect
aureu
h
infruenza
consid
quantit
bacteriolog
examin
sputum
test
antibiot
suscept
bacteri
isol
also
necessari
optom
antibacteri
therapi
contrast
chronic
obstruct
pulmonari
diseas
pneumonia
found
detect
pneumonia
sputum
patient
cystic
fibrosi
rather
difficult
even
select
procedur
inhibit
growth
p
aeruginosa
serolog
studi
progress
determin
preval
pneumonia
acut
exacerb
found
evid
signific
chang
concern
number
cfu
albican
aspergillu
fumigatu
sputum
viral
respiratori
ill
although
c
albican
second
frequent
microorgan
high
antibodi
titer
c
albican
role
respiratori
viral
bacteri
mycoplasma
c
p
aeruginosa
cystic
fibrosi
still
unclear
one
sixyearold
girl
p
aeruginosa
could
detect
first
time
nasopharyng
swab
infect
parainfluenza
viru
type
anoth
patient
intermitt
colon
p
aeruginosa
harbour
p
aeruginosa
bronchial
system
infect
influenza
viru
disappear
sputum
p
aeruginosa
reappear
second
influenza
viru
infect
contrast
petersen
et
emphasis
import
infect
due
rsv
found
highest
incid
influenza
viru
follow
adenoviru
predomin
role
influenza
viru
may
associ
higher
level
respiratorytract
proteas
cystic
fibrosi
incud
proteolyt
cleavag
influenza
viru
hemagglutinin
requir
penetr
viru
epitheli
cell
low
rate
significantli
increas
ospecif
sigaantibodi
infect
influenza
viru
contrast
viral
agent
might
relat
suppress
humor
immun
system
viru
take
incub
period
time
requir
seroconvers
account
onethird
serolog
evid
viral
infect
seem
nosocomi
infect
determin
serotypespecif
antibodi
adenoviru
could
prove
whether
three
infect
caus
adenoviru
due
cross
infect
donati
et
demonstr
home
therapi
cystic
fibrosi
patient
pulmonari
exacerb
effect
hospit
therapi
possibl
patient
cystic
fibrosi
acquir
viral
respiratori
ill
hospit
emphasis
import
home
therapi
result
studi
show
clearli
import
viral
respiratori
tract
infect
cystic
fibrosi
cystic
fibrosi
patient
vaccin
influenza
chemoprophylaxi
amantadin
treatment
ribavirin
consid
futur
develop
includ
diagnosi
respiratori
viral
ill
well
product
vaccin
adenoviru
parainfluenza
viru
rsv
studi
progress
elucid
role
viral
bacteri
infect
establish
primari
colonis
p
aeruginosa
bronchial
system
patient
cystic
fibrosi
